Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA2 | P00918 | 2/20 | 0.47 |
| ▸ | CA12 | O43570 | 1/20 | 0.47 |
| ▸ | CA1 | P00915 | 1/20 | 0.47 |
| ▸ | CA7 | P43166 | 1/20 | 0.47 |
| ▸ | CA9 | Q16790 | 1/20 | 0.47 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.47 |
| ▸ | PDGFRB | P09619 | 1/20 | 0.42 |
| ▸ | PDGFRA | P16234 | 1/20 | 0.42 |
| ▸ | TUBB4A | P04350 | 2/20 | 0.36 |
| ▸ | TUBB | P07437 | 2/20 | 0.36 |
| ▸ | TUBA3C | P0DPH7 | 2/20 | 0.36 |
| ▸ | TUBA1B | P68363 | 2/20 | 0.36 |
| ▸ | TUBA4A | P68366 | 2/20 | 0.36 |
| ▸ | TUBB4B | P68371 | 2/20 | 0.36 |
| ▸ | TUBB3 | Q13509 | 2/20 | 0.36 |
| ▸ | TUBB2A | Q13885 | 2/20 | 0.36 |
| ▸ | TUBB8 | Q3ZCM7 | 2/20 | 0.36 |
| ▸ | TUBA3E | Q6PEY2 | 2/20 | 0.36 |
| ▸ | TUBA1A | Q71U36 | 2/20 | 0.36 |
| ▸ | TUBA1C | Q9BQE3 | 2/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2751899 | 0.89 | CA12 (0.50) | CA2CA12CA1CA7CA9 | |
| SCHEMBL2751578 | 0.89 | CA12 (0.50) | CA2CA12CA1CA7CA9 | |
| SCHEMBL2092777 | 0.82 | MEN1 (0.44) | CA2CA12CA1CA7CA9 | |
| SCHEMBL2752051 | 0.78 | ALDH1A1 (0.41) | CYP1A1CYP1B1CYP1A2ALDH1A1MAPK1 | |
| SCHEMBL2753073 | 0.78 | HAO1 (0.35) | — | |
| SCHEMBL2752261 | 0.78 | HAO1 (0.47) | ALDH1A1HTTL3MBTL1 | |
| SCHEMBL2095700 | 0.76 | MEN1 (0.53) | ACHEALDH1A1HTTGAA | |
| SCHEMBL2753033 | 0.74 | SMN1; SMN2 (0.47) | CA2CA12CA1CA7CA9 | |
| SCHEMBL2094912 | 0.74 | HAO1 (0.47) | — | |
| SCHEMBL126301 | 0.73 | CA2 (0.76) | CA2CA12CA1CA7CA9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-101541764-B | Pyrimidylmethyl-sulfonamide compounds useful as fungicides and against arthropods | BASF SE | 2012-10-10 | — | — | CN | disclosed |
| US-8178540-B2 | Pyrimidylmethyl-sulfonamide compounds | BASF SE (DE) | 2012-05-15 | — | — | US | disclosed |
| US-8163753-B2 | 2-(4-(4-(4-chlorophenyl)oxazol-2-yl)phenoxymethyl)-2-methyl-6-nitro-2,3-dihydroimidazo[2,1-b]oxazole; bactericide; excellent bactericidal action against Mycobacterium tuberculosis, multi-drug-resistant Mycobacterium tuberculosis, and atypical acid-fast bacteria | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2012-04-24 | — | — | US | disclosed |
| US-20100077512-A1 | Pyridazin-4-ylmethyl-sulfonamides used as Fungicides and Against Arthropods | BASF SE (DE) | 2010-03-25 | — | — | US | disclosed |
| US-20100069243-A1 | Pyrimidylmethyl-Sulfonamide Compounds | BASF SE (DE) | 2010-03-18 | — | — | US | disclosed |
| EP-1678185-B1 | 2,3-DIHYDRO-6-NITROIMIDAZO [2,1-B] OXAZOLE COMPOUNDS FOR THE TREATMENT OF TUBERCULOSIS | OTSUKA PHARMA CO LTD (JP) | 2008-10-08 | — | — | EP | disclosed |
| US-20080119478-A1 | 2,3-Dihydro-6-Nitroimidazo (2,1-b) Oxazole Compounds for the Treatment of Tuberculosis | OTSUKA PHAMACEUTICAL CO., LTD. (JP) | 2008-05-22 | — | — | US | disclosed |
| EP-1678185-A1 | 2,3-DIHYDRO-6-NITROIMIDAZO [2,1-B] OXAZOLE COMPOUNDS FOR THE TREATMENT OF TUBERCULOSIS | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2006-07-12 | — | — | EP | disclosed |
| WO-2005042542-A1 | 2,3-DIHYDRO-6-NITROIMIDAZO (2,1-B) OXAZOLE COMPOUNDS FOR THE TREATMENT OF TUBERCULOSIS | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2005-05-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100069243-A1 | Pyrimidylmethyl-Sulfonamide Compounds | TPMT, NISCH, PPA1 | CA2 1278/4885CA12 3457/4885CA1 3730/4885 |
| US-20080119478-A1 | 2,3-Dihydro-6-Nitroimidazo (2,1-b) Oxazole Compounds for the Treatment of Tuberculosis | NR2C2, NR0B2, NR4A2 | CA2 2002/4885CA12 3179/4885CA1 4171/4885 |
| US-20100077512-A1 | Pyridazin-4-ylmethyl-sulfonamides used as Fungicides and Against Arthropods | PIR, PRDX4, PRDX2 | CA2 579/4885CA12 2393/4885CA1 3207/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.